Novavax, Inc. (NVAX, 81.29)is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS). The EPS of 2020 and 2021 is estimated at $9.01 and $26.13 respectively. It represents a turnaround and an increase of 290% from prior year. The revenue of 2020 and 2021 is expected to be 35.54 million and 230.56 million. Also represents an increase of 1,051% and 648.7% from prior year. Buy it at $81.29 or lower and sell it at $152 or higher.(投資有風險，請謹慎評估，若決定購買，請自設停損）
法律聲明： 我目前持有以上的股票 (美西時間： 05:04 AM 10-29-20)
追蹤行動：
|
字體：小 中 大
